🇺🇸 FDA
Patent

US 11266724

Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

granted A61KA61K2039/505A61K31/7105

Quick answer

US patent 11266724 (Modified factor VII polypeptides for subcutaneous administration and on-demand treatment) held by Catalyst Biosciences, Inc. expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Catalyst Biosciences, Inc.
Grant date
Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K31/7105, A61K38/4846, A61K39/3955